Ayala Pharmaceuticals, Inc. (AYLA)
| Market Cap | 27.04M |
| Revenue (ttm) | 2.99M |
| Net Income (ttm) | -40.71M |
| Shares Out | 14.09M |
| EPS (ttm) | -2.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,972 |
| Open | 2.04 |
| Previous Close | 1.95 |
| Day's Range | 1.86 - 2.11 |
| 52-Week Range | 1.86 - 14.95 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 15.17 (+690.1%) |
| Earnings Date | May 13, 2022 |
About AYLA
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small m...
Financial Performance
In 2021, AYLA's revenue was $3.51 million, a decrease of -5.45% compared to the previous year's $3.71 million. Losses were -$40.25 million, 33.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for AYLA stock is "Buy." The 12-month stock price forecast is 15.17, which is an increase of 690.10% from the latest price.
News
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 Interim data from Part A of RINGSIDE study of AL102 expected mid-2022
Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO)...
REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...
Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
- Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – - Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –
Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...
Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...
How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%
The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is quest...
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 –
Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mole...
Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline
Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) ha...
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from C...
REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -19.05% and -25.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...
Recap: Ayala Pharmaceuticals Q2 Earnings
Shares of Ayala Pharmaceuticals (NASDAQ:AYLA) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 1.35% over the past year to ($0.75), which missed the e...
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors
Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know
Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecu...
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
- First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for the Treatment of Multiple Myeloma -
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targe...
REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mol...
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
Ayala Pharmaceuticals Inc (NASDAQ: AYLA) will raise $25 million via a private placement of around 1.7 million units at $15 per unit from institutional investors, including Redmile Group and SIO Capital ...
Ayala Pharmaceuticals Announces $25 Million Strategic Financing
Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023